Cohance Lifesciences: Can ADCs Become the Next Growth Driver

# Cohance Lifesciences: Can ADCs Become the Next Growth Driver? Cohance Lifesciences, formerly Suven Pharmaceuticals, is building an integrated pharmaceutical services platform spanning CDMO, APIs, formulations and specialty capabilities. **What is changing?** The company is increasingly focusing on high-value CDMO opportunities, including antibody-drug conjugates (ADCs). Its investment in NJ Bio provides access to specialised ADC capabilities, while Cohance has continued developing its broader bioconjugation platform. The company announced further progress on its ADC strategy in September 2026. **Why does this matter?** ADCs combine targeted biological therapies with potent drug payloads and are attracting increasing interest from global pharmaceutical companies. For a CDMO, participation in this segment could potentially provide higher-value contracts and deeper relationships with innovators. **What investors should track** - New CDMO contracts and customer additions - ADC and bioconjugation capacity utilisation - Revenue contribution from high-value projects - Regulatory clearances and compliance - Cash flow and returns on expansion **Key takeaway:** Cohance’s long-term opportunity lies in moving towards specialised, higher-value pharmaceutical services. Successful execution in ADCs and complex CDMO programs could strengthen the business mix, but commercialisation, regulatory execution and return on invested capital remain key variables. **Disclosure:** I am a SEBI Registered Research Analyst. This content is for educational purposes and is not a recommendation to buy or sell any security. **Suggested tags:** Fundamental Views + Equity Research + Pharmaceuticals